INTRODUCTION
In critically ill patients, the harmful effects of a reduction oxygen (O 2 ) availability are well known and feared, whereas the potential negative effects of an excess of O 2 at the tissue level are rarely considered. In fact, supplemental O 2 is one of the most frequently applied therapies and supernormal values of arterial O 2 tension (PaO 2 ) are often tolerated in patients admitted to intensive care Units (ICUs) as perceived as a safety buffer against hypoxemia [1, 2] . As a result, a large proportion of patients is at risk of being exposed to excessive O 2 administration [3] .
Oxygen has not always been such a 'vital' element: life on earth initially developed in an extremely hypoxic environment. With the O 2 concentration progressively rising in the atmosphere, the evolutionary pressure favoured those life forms that were able to survive O 2 toxicity, finally leading to the development of mitochondria, eukaryotic organisms and multicellular aerobic life [4] . The paradox of O 2 molecule remains in its capacity of exerting deleterious effects on the very life forms for which it has become an essential component of energy production [5] . Increasing evidence shows that the exposure to hyperoxemia during critical illness is associated with worse outcome [6, 7] and a conservative O 2 therapy aimed to avoid a substantial exposure to hyperoxia may be advantageous [8] . We reviewed the biological effects of hyperoxia with particular focus on the potential harms from excessive O 2 administration and discussed the clinical studies evaluating O 2 therapy in different subsets of critically ill patients.
The term 'hyperoxia' generically refer to an excess O 2 supply, that is, the administration of any inspired O 2 fraction higher than 0.21. In an individual with normal respiratory function, this will lead to 'hyperoxemia' or 'arterial hyperoxia,' a condition in which the PaO 2 rises above normal values. As a PaO 2 range of 80-100 mmHg is generally used to define normoxemia in an individual breathing room air at sea level, any PaO 2 value greater than 100 mmHg will virtually reflect a condition of hyperoxemia. However, varying criteria have been used in clinical studies to define hyperoxemia, leading to highly inconsistent results [6] . In most observational studies, patients were categorized as hyperoxemic or nonhyperoxemic based on arbitrarily predetermined PaO 2 cut-offs, ranging from values as high as 300 mmHg to less extreme PaO 2 levels of 200 or 120 mmHg [6, 7] . Whenever the PaO 2 was analyzed as a continuous variable, a linear relationship between increasing O 2 tensions and mortality was found, without a clear threshold for harm [8, 9] . Different metrics of arterial hyperoxia have been applied in different studies, including the first, highest, average or worst PaO 2 [6, 7] . Most of these measures were assessed in the first 24 h of ICU admission, whereas longer time periods of exposure were considered only in a few cases [6, 7] . A recent cohort study showed that the incidence of hyperoxemia in the ICU, as well as the strength of the association with worse outcome, greatly varied depending on the particular metric applied, with metrics of central tendencies (mean and median PaO 2 ) showing the strongest relationship with outcome [10 & ]. Although severe hyperoxemia (PaO 2 >200 mmHg) was more consistently associated with adverse outcome, mortality appeared to increase linearly with the exposure time even within a mild hyperoxemia range (PaO 2 of 120-200 mmHg) [10 & ].
BIOLOGICAL EFFECTS OF HYPEROXIA
Oxidative stress is the unavoidable consequence of O 2 breathing [5] . A variety of antioxidant molecules is available in the mitochondrion to detoxify the reactive oxygen species (ROS) generated during aerobic metabolism processes. Systemic inflammation and shock states may induce an over production of ROS exceeding the antioxidant defences. In this setting, excess O 2 administration may contribute to the imbalance between pro-oxidants and antioxidants and aggravate oxidative stress, causing damage to nucleic acids, proteins and lipids with potential cell death and exacerbation of the inflammatory response [11] . The lung is the first organ involved by the excessive use of O 2 in the inspired mixture. The exposure to 100% O 2 caused inflammation and oxidative stress in mouse lungs, with an increase in pro-inflammatory cytokines and number of macrophages and neutrophils, culminating in histological tissue damage [12] . Helmerhorst et al. [13 & ] found a dose-dependent and time-dependent inflammatory pulmonary response in mice exposed to several degrees of hyperoxia. The nitric oxide (NO) pathway appears to play a key role. Increasing levels of NO are produced by the inducible-NO synthase (i-NOS) in epithelial, endothelial and immune cells during inflammation. The exposure to hyperoxia, by enhancing oxidative stress, may cause an important production of peroxynitrite, a cytotoxic oxidant generated from the reaction between NO and superoxide. Hesse et al. [14] showed blunted hyperoxia-induced lung injury in i-NOS knockout mice as compared with wild type. Hyperoxia can induce cell death in the lungs by modulating the expression of cell survival/death regulating genes such as c-myc and bax [15] or by inducing caspase-mediated apoptosis [16] . Hyperoxia may also impair the surfactant system with down-regulation of surfactant-associated protein [15, 17] , alveolar instability and reduction in lung compliance especially during high-tidal volume ventilation [18] . In addition, resorption atelectasis occur after breathing high O 2 concentrations because of denitrogenation, a process by which nitrogen is displaced by O 2 that diffuses more rapidly into the blood, leading to alveolar collapse [19] . Excess O 2 supply also impairs mucociliary clearance and the antimicrobial capacity of immune cells. Hyperoxia aggravated lung injury and increased lethality in mice with pulmonary infections [20] [21] [22] . The number of days spent with hyperoxemia
KEY POINTS
Excess O 2 supplementation may have detrimental pulmonary and systemic effects by enhancing oxidative stress and inflammation and inducing vasoconstriction and alteration in microvascular perfusion. O 2 administration in nonhypoxemic patients showed no clear benefit in myocardial infarction, stroke, traumatic brain injury, cardiac arrest and sepsis, and may even cause harm.
The current evidence supports a more conservative O 2 therapy with precise control of arterial oxygenation, using individualized oxygenation targets to limit exposure to both hypoxemia and hyperoxemia.
was also an independent risk factor for ventilatorassociated pneumonia [23 & ].
Enhanced oxidative stress may have also a systemic impact in hyperoxemia. In an animal model of sepsis, the exposure to hyperoxia for 24 h was associated with higher increase in serum ROS and inflammatory cytokines, greater spread of infection and worse multiple organ dysfunction [24] . In rats subjected to progressive hemorrhage, hyperoxemia compromised hemodynamics and organ perfusion similarly to hypoxemia and was associated with higher increase in lactate levels [25] . Hyperoxemia induces vasoconstriction and increases systemic vascular resistance with consequent reductions in heart rate, stroke index and cardiac index [26] . Hyperoxia is associated with reductions in coronary blood flow and myocardial oxygen consumption [27] . A reduced bioavailability of the vasodilator NO because of oxidative stress seems the main factor responsible for vasoconstriction [28] , although a recent study using isolated microvascular endothelial cells also showed a decreased cell viability and proliferation under hyperoxia [29] . Studies using sublingual video-microscopy showed that the administration of 100% O 2 is associated with a reduction in microvascular density in animal models [30 & ] and in healthy volunteers [31] . In mechanically ventilated patients, hyperoxia induced early reductions in sublingual microcirculatory density and perfusion [32] . Similar microvascular alterations were found in postoperative patients with coronary artery by-pass grafting, where short-term hyperoxia led to vasoconstriction of both the venous and arterial circulation, with an increase in stressed volume and mean systemic filling pressure [33] . The impairment in microvascular perfusion can induce a paradoxical reduction in regional O 2 delivery [34] , although other reports have suggested a beneficial role of hyperoxia in hemodynamic stabilization and redistribution of blood flow to splanchnic organs in animal shock models [35, 36 & ].
CONSERVATIVE VERSUS LIBERAL OXYGEN THERAPY IN ICU PATIENTS
Conflicting data exist on the relationship between hyperoxemia and outcome in mixed ICU patients because of the heterogeneous methods applied in observational studies, which showed either no relationship [37] Table 1 ). The use of lower SpO 2 targets appeared feasible and well tolerated and was associated with a decrease in pulmonary atelectasis [40] , an increase in ventilator-free days [40, 41] and lower mortality [41] . The single-centre Oxygen-ICU study was the first randomized controlled trial (RCT) to show that a more conservative O 2 therapy using an SpO 2 target of between 94 and 98% was able to reduce ICU mortality and was associated with lower incidence of new infections and shock [42 && ]. Nonetheless, these ], even though the overall analysis indicated no difference in mortality, the prespecified sub-group analysis of patients with respiratory failure showed a lower mortality in conservative O 2 strategy group than in the liberal one, with an absolute risk reduction similar to that observed in the Oxygen-ICU trial [42 && ]. The multicentre randomized O 2 -ICU (Optimal Oxygenation in Intensive Care Unit) study is currently ongoing and will compare a low-normal (60-90 mmHg) to a high-normal (105-135 mmHg) PaO 2 target in critically ill patients with a systemic inflammatory response syndrome (NCT02321072).
OXYGEN THERAPY IN PATIENTS WITH STROKE AND TRAUMATIC BRAIN INJURY
Preclinical studies yielded promising results with O 2 therapy in stroke, showing a reduction in infarct size, slower blood-brain barrier damage, decreased risk for secondary hemorrhage after thrombolysis [44] . Nonetheless, apart from some encouraging pilot data [45] , clinical studies were not able to demonstrate any protective effect of O 2 therapy in patients with cerebrovascular incidents. A relationship between hyperoxemia and adverse outcomes was observed in patients with stroke [46] and subarachnoid hemorrhage [47] , wherever higher PaO 2 was associated with greater risk of delayed cerebral ischemia, although this relationship was not confirmed by other studies [48] [49] [50] . Different protocols of O 2 therapy were investigated by RCTs (Table 2) without any clear benefit [51] [52] [53] [54] [55] . The Stroke Oxygen Study was the largest RCT that evaluated the effects of a low-dose O 2 supplementation and did not find any difference in morbidity or mortality with the control arm [56 && ]. Another RCT testing the impact of high-flow O 2 administration was terminated early because of an imbalance in deaths favouring the control arm (NCT00414726).
In traumatic brain injury (TBI), the rationale for hyperoxia is to improve brain O 2 delivery and cerebral perfusion by allowing a reduction in intracranial pressure because of vasoconstriction. In fact, hyperbaric O 2 therapy appeared as a promising adjunctive treatment in this setting [57] . In a phase II RCT, the combination of hyperbaric and normobaric O 2 therapy was able to ]. However, other evidences showed potential harm from arterial hyperoxia. Higher inspired O 2 concentrations caused increased cerebral excitotoxicity in patients with severe TBI, suggesting that hyperoxemia may aggravate secondary brain damage [60] . Meta-analyses of observational trials showed an association between hyperoxemia and mortality, despite high inconsistency between the studies [6, 7] . In a recent cohort study in trauma patients, no association was found between the maximum PaO 2 within 24 h of admission and mortality in the subgroup of patients with head trauma [61] . The BRAINOXY Study (NCT01201291), a RCT comparing 70 versus 40% O 2 therapy in TBI, was terminated early because of slow recruitment. Therefore, a clear benefit of hyperoxia in this condition remains to be proven.
OXYGEN THERAPY IN ACUTE MYOCARDIAL INFARCTION AND CARDIAC ARREST
Supplemental O 2 has been routinely used for more than a century in the management of acute coronary syndromes [62] , with the rationale of increasing O 2 supply to the ischemic myocardium. In the last few years, increasing evidence showed that hyperoxemia may induce a reduction in coronary blood flow [27] with paradoxical increase in myocardial ischemia [63] and aggravates myocardial ischemia/reperfusion injury [64] . Clinical studies evaluating supplemental O 2 therapy in patients with acute myocardial infarction (AMI) showed no effect or even harm, with higher incidence of recurrent ischaemia and increase in infarct size in case of [65 & ]. The DETO2X-SWEDEHEART study showed no benefit of supplemental O 2 as compared with air on all-cause mortality at 1 year in nonhypoxemic patients with suspected AMI [66 && ]. On the basis of these data, the 2017 Guidelines of the European Society of Cardiology for the management of ST-segment elevation myocardial infarction do not recommend the routine use of O 2 for patients with an SaO 2 at least 90% [67 && ]. In cardiac arrest, O 2 therapy at high concentrations is routinely used during cardiopulmonary resuscitation and in the postresuscitation phase to increase O 2 availability at the tissue level. Nonetheless, potential detrimental effects of hyperoxemia and ROS toxicity have been demonstrated in this condition of extreme global ischemia/reperfusion syndrome over the last decades [68] . In animal models, the administration of 100% O 2 after resuscitation from cardiac arrest led to worse neurological outcomes as compared with lower O 2 concentrations [69] . Several authors found an association between exposure to hyperoxemia after resuscitation and mortality [6, 7, 70, 71] or worse neurological outcome [8, 9, 72] , although these findings were not confirmed by others [73, 74] . A pilot RCT showed an increase at 24 h of neuronal injury markers in postcardiac arrest patients ventilated with 100% O 2 rather than 30% O 2 [75] . A multicentre feasibility study to compare titrated versus standard O 2 therapy in patients resuscitated from out-of-hospital cardiac arrest was stopped early because continuous O 2 titration against SpO 2 measurements appeared not feasible in the prehospital setting because of unreliable SpO 2 recordings [76] .
OXYGEN THERAPY IN SEPSIS
It is reasonable to expect that excess O 2 supplementation during sepsis may aggravate oxidative stress and inflammatory response, thereby worsening organ function [24] . Nonetheless, preclinical data are controversial and the use of 100% O 2 was advocated by some authors for its potential to counteract shock-induced hypotension, increase peripheral microvascular flow, attenuate tissue apoptosis and improve organ function, in addition to exerting antibiotic effects [35,36 & ,77]. The recent published HYPERS2S Study was a two-by-two factorial multicentre RCT that evaluated the effect of normobaric hyperoxia in the first 24 h and hypertonic saline solution in patients with septic shock. The study was terminated prematurely after recruitment of 442 patients for safety reason: hyperoxia was associated with higher risk of mortality and serious adverse events, including ICU-acquired weakness and atelectasis [78 && ]. The ongoing Trial of Hyperoxic O 2 Therapy versus Normoxic O 2 Therapy in Sepsis (HO2T or NO2T) will provide important information on the effects of high flow O 2 in patients with sepsis admitted to the emergency department (NCT02378545).
CONCLUSION
Clinicians must be aware that supplemental O 2 in nonhypoxemic patients leads to a marginal increase in systemic O 2 delivery, but it may have serious adverse effects on inflammation, oxidative stress, pulmonary function, microvascular perfusion, coronary and cerebral blood flow. To date, there is no sufficient evidence to support a liberal O 2 supplementation in any subset of critically ill patients. A more conservative O 2 therapy in critically ill patients appears well tolerated and may improve outcome. Therefore, unnecessary O 2 administration should be avoided and the exposure to hyperoxemia minimized. This requires a revision of the traditional approach to O 2 therapy whose priority has been the prevention of hypoxemia accepting supernormal PaO 2 levels also for prolonged periods. A strategy of precise control of arterial oxygenation wherever O 2 therapy is titrated against a prespecified PaO 2 or SaO 2 target range seems to be the most appropriate approach [79] . The best PaO 2 target may vary based on patient-related factors, such as age, comorbidities and underlying disease. For example, a wider PaO 2 target could be accepted in an otherwise healthy middle-aged individual undergoing elective noncancer surgery, whereas a significantly narrower target could be auspicated for a septic patient with a history of cardiac ischemia, wherever both hypoxemia and hyperoxemia may be detrimental. Martin et al. [79] proposed a strategy of permissive hypoxemia for critically ill patients requiring high O 2 concentrations to maintain normoxemia, with the rationale of limiting O 2 toxicity by targeting lower PaO 2 levels in selected patients who had sufficient time to adapt to hypoxemia. However, the safety and efficacy of this strategy need to be verified [80] .
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